Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Asset Utilization Ratio (2016 - 2025)

Historic Asset Utilization Ratio for Karyopharm Therapeutics (KPTI) over the last 13 years, with Q4 2025 value amounting to 1.43.

  • Karyopharm Therapeutics' Asset Utilization Ratio rose 7391.64% to 1.43 in Q4 2025 from the same period last year, while for Dec 2025 it was 1.43, marking a year-over-year increase of 7391.64%. This contributed to the annual value of 1.07 for FY2025, which is 4923.71% up from last year.
  • Latest data reveals that Karyopharm Therapeutics reported Asset Utilization Ratio of 1.43 as of Q4 2025, which was up 7391.64% from 1.42 recorded in Q3 2025.
  • In the past 5 years, Karyopharm Therapeutics' Asset Utilization Ratio registered a high of 1.43 during Q4 2025, and its lowest value of 0.36 during Q2 2021.
  • Moreover, its 5-year median value for Asset Utilization Ratio was 0.72 (2024), whereas its average is 0.75.
  • As far as peak fluctuations go, Karyopharm Therapeutics' Asset Utilization Ratio skyrocketed by 15056.45% in 2022, and later tumbled by 4983.47% in 2023.
  • Over the past 5 years, Karyopharm Therapeutics' Asset Utilization Ratio (Quarter) stood at 0.75 in 2021, then fell by 28.95% to 0.53 in 2022, then rose by 7.36% to 0.57 in 2023, then surged by 43.44% to 0.82 in 2024, then soared by 73.92% to 1.43 in 2025.
  • Its last three reported values are 1.43 in Q4 2025, 1.42 for Q3 2025, and 1.18 during Q2 2025.